Specific case information on multiple fusion.

The current ALINA trial focused on the EML4-ALK fusion protein second-generation drug alectinib, which enrolled 257 patients with ALK-positive NSCLC in stage IB-IIIA (N2) (7th edition AJCC staging), ...

George R. Tynan has received research funding from the US Department of Energy and the Office of Fusion Energy Sciences, and has served on numerous advisory panels to DOE and the International ...

Over the decades, and influenced by the geopolitics of energy and the need for cleaner sources to power our lives in the era of climate change, civilian efforts have focused on sustaining stable ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

The airline explains a new development.

1 Day ALK 3.09% DJIA 0.38% S&P 500 0.53% Transportation/Logistics -0.27% ...